Arctos NorthStar Acquisition Corp. ANAC
10.19 0.00 (+0.00%)
Feb 24, 2023, 3:08 PM EST
10.19 Day range 10.19
9.74 52-week range 10.19
- Market cap
- 402.82M
- EPS (ttm)
- 0.31
- Shares out
- 31.63M
- P/E ratio
- 32.87
- Volume
- 705
- Avg volume
- 146.10K
- Open
- 10.19
- Previous close
- 10.19
- Day's range
- 10.19 – 10.19
- 52-week range
- 9.74 – 10.19
No chart data for this range yet.
Key statistics
- Enterprise value
- 403.17M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 205.81K
- Total debt
- 550.00K
- Return on equity
- 0.00%
- Short % of float
- 0.02%
- 50-day average
- 10.13
- 200-day average
- 9.95
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
ANAC Revenue — quarterly 0
ANAC Net income — quarterly 2.12M
ANAC EPS — quarterly 0.05
About Arctos NorthStar Acquisition Corp.
Arctos NorthStar Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It focuses on sports, media, and entertainment sectors. The company was founded in 2020 and is based in Dallas, Texas.
- Sector
- Financial Services
- Industry
- Shell Companies
- Country
- United States
- Website
- arctosnorthstar.com
News
ANAC Publishes Proposed Noise Certification Criteria for Eve 100 
ANAC Publishes Proposed Noise Certification Criteria for Eve 100 
Lakeland Fire + Safety Awarded Fire Equipment Tender by Argentina's National Civil Aviation Administration ANAC 
McCauley Propeller secures ANAC certification for Beechcraft King Air B300 series high-performance propeller 
Anacor Pharmaceuticals to Report First Quarter 2016 Financial Results
on May 10, 2016 
Anacor Pharmaceuticals Announces 2015 Fourth Quarter and Year-End
Financial Results Conference Call and Webcast 
Anacor Pharmaceuticals to Report Third Quarter 2015 Financial Results
on November 3, 2015 
Anacor Pharmaceuticals to Report Second Quarter 2015 Financial
Results on August 6, 2015 
Anacor Pharmaceuticals Announces Positive Top-Line Results From Two
Phase 3 Pivotal Studies of Crisaborole Topical Ointment, 2% in Patients
With Mild-to-Moderate Atopic Dermatitis 
Anacor Pharmaceuticals Announces First Quarter 2015 Financial Results
Conference Call and Webcast
Your note
Sign in to keep a note on ANAC — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Glazer Capital LLC | 9.90% | 3,130,152 | 31.90M | Dec 30, 2022 |
| Aristeia Capital, LLC | 7.06% | 2,232,527 | 22.75M | Dec 30, 2022 |
| Sculptor Capital Lp | 4.04% | 1,278,676 | 13.03M | Dec 30, 2022 |
| Shaw D.E. & Co., Inc. | 3.84% | 1,213,146 | 12.36M | Dec 30, 2022 |
| Millennium Management Llc | 3.63% | 1,146,998 | 11.69M | Dec 30, 2022 |
| Marshall Wace LLP | 3.30% | 1,042,812 | 10.63M | Dec 30, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Investment Managers Ser Tr II-First Trust Merger Arbitrage Fd | 0.41% | 128,996 | 1.31M | Sep 29, 2022 |
| Blackstone Alternative Multi-Strategy Fund | 0.13% | 39,804 | 405.60K | Sep 29, 2022 |
| Saba Capital Income & Opportunities Fd | 0.13% | 39,600 | 403.52K | Oct 30, 2022 |
| Nationwide Multi Cap Portfolio | 0.00% | 201 | 2.05K | Oct 30, 2022 |